Drug Development in NMIBC from Scientific, Regulatory, Clinician, and Patient Perspectives (2021)
America/New York GMT -4 summer
Peter Black, Jonathan Coleman
Opening Remarks, Recap from Previous Day, and Goal Setting, SESSION THREE: Risk Stratification of NMIBC Through Genomics and Immunobiology, Predicting Response to BCG, Can We Identify Patients Who Should Undergo Immediate Cystectomy?, The Role of Radiology and Radiomics in Staging and Risk Stratification of NMIBC, Understanding the Microenvironment of NMIBC and Possible Future Immune Targets, Discussion and Q&A, SESSION FOUR: Treatment of Non-Muscle-Invasive Urothelial Cancer of the Upper Tract, Novel and Multimodality Management Strategies for Localized UTUC, Special Considerations for UTUC and Lynch Syndrome, Genomics of UTUC, Perioperative Chemotherapy and Targeted Therapy for Locally Advanced UTUC, Discussion, Q&A, Closing Remarks
Previous registration necessary?
Simultaneous translation ?
Will it be recorded?
Matthew Galsky, Yair Lotan, Max Kates, Joaquim Bellmunt, Manjiri Dighe, Amir Horowitz, Surena Matin, Jennifer Taylor, Bishoy Faltas, Vitaly Margulis